ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2012-11-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/378 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850084443565326336 |
|---|---|
| author | saveria capria silvia maria trisolini clara minotti caterina stefanizzi luisa cardarelli Martina Canichella claudio cartoni daniela diverio maria stefania de propris marco mancini alessandra micozzi robin foà giovanna meloni |
| author_facet | saveria capria silvia maria trisolini clara minotti caterina stefanizzi luisa cardarelli Martina Canichella claudio cartoni daniela diverio maria stefania de propris marco mancini alessandra micozzi robin foà giovanna meloni |
| author_sort | saveria capria |
| collection | DOAJ |
| description | Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation.
We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant.
Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant. |
| format | Article |
| id | doaj-art-ea3446d2dea445d1923152e86a43ca76 |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2012-11-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-ea3446d2dea445d1923152e86a43ca762025-08-20T02:44:02ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062012-11-0141e2012072e201207210.4084/mjhid.2012.072270ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTSsaveria capria0silvia maria trisolini1clara minotti2caterina stefanizzi3luisa cardarelli4Martina Canichellaclaudio cartoni5daniela diverio6maria stefania de propris7marco mancini8alessandra micozzi9robin foà10giovanna meloni11Sapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaSapienza Università di RomaLong-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant. Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.http://www.mjhid.org/index.php/mjhid/article/view/378LeukemiaGentuzumab OzogamicinAllogeneic stem cell transplantation |
| spellingShingle | saveria capria silvia maria trisolini clara minotti caterina stefanizzi luisa cardarelli Martina Canichella claudio cartoni daniela diverio maria stefania de propris marco mancini alessandra micozzi robin foà giovanna meloni ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS Mediterranean Journal of Hematology and Infectious Diseases Leukemia Gentuzumab Ozogamicin Allogeneic stem cell transplantation |
| title | ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS |
| title_full | ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS |
| title_fullStr | ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS |
| title_full_unstemmed | ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS |
| title_short | ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS |
| title_sort | ara c idarubicine and gentuzumab ozogamicin aim as salvage treatment in advanced acute myeloid leukemia patients |
| topic | Leukemia Gentuzumab Ozogamicin Allogeneic stem cell transplantation |
| url | http://www.mjhid.org/index.php/mjhid/article/view/378 |
| work_keys_str_mv | AT saveriacapria aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT silviamariatrisolini aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT claraminotti aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT caterinastefanizzi aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT luisacardarelli aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT martinacanichella aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT claudiocartoni aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT danieladiverio aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT mariastefaniadepropris aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT marcomancini aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT alessandramicozzi aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT robinfoa aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients AT giovannameloni aracidarubicineandgentuzumabozogamicinaimassalvagetreatmentinadvancedacutemyeloidleukemiapatients |